Eris Lifesciences Ltd shared an investor presentation outlining its financial performance for Q2 FY25, reporting operational revenue of INR 644 crore and EBITDA margin of 37%, while projecting a total revenue of INR 2,600 crore for FY25 with a 9-10% growth in its base business.